Market Spotlight: Obesity
Market Spotlight: Obesity
$1,318.00
This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecast
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecast
Key Takeaways
- Datamonitor Healthcare estimates that in 2021, there were approximately 694.0 million prevalent cases of obesity in adults (aged 20+ years) worldwide, and expects that number to increase to 758.5 million prevalent cases by 2029.
- In the same year, Datamonitor Healthcare estimates that there were 126.3 million prevalent cases of obesity in children and adolescents (aged 5–19 years) worldwide, and expects that number to increase to 128.3 million prevalent cases by 2029.
- Prevalence proportions are highest in Northern America and lowest in Asia. The approved drugs in the obesity space target gastric lipase, dopamine, norepinephrine (noradrenaline), dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, opioid receptors, GABA-A receptor, and glucagon-like peptide-1 (GLP-1) receptor. The majority of marketed drugs are administered via the oral route, with two products being available in a subcutaneous formulation.
- The largest proportion of industry-sponsored drugs in active clinical development for obesity are in Phase I, with two drugs in Phase III.
- Therapies in development for obesity focus on a wide variety of targets. These therapies are commonly administered via the subcutaneous or oral routes, with one drug being tested in an intravenous formulation.
- High-impact upcoming events for drugs in the obesity space comprise topline Phase II trial results for PF-06882961, pemvidutide, and ARD-101; topline Phase IIb trial results for Tesomet; topline Phase III trial results for Mounjaro; and an estimated EU patent expiration for Qsymia.
- The overall likelihood of approval of a Phase I obesity asset is 2.3%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 8.3 years from Phase I to approval, compared to 9.8 years in the overall metabolic space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for obesity have been in the early and midphases of development, with 64% of trials in Phase I–II, and 36% in Phase III–IV.
- The US has a substantial lead in the number of obesity clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the obesity space is dominated by completed trials. Novo Nordisk has the highest number of completed clinical trials for obesity, with 86 trials.
- Novo Nordisk leads industry sponsors with the highest overall number of clinical trials for obesity, followed by AstraZeneca.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Medications
9 Surgery
11 EPIDEMIOLOGY
19 MARKETED DRUGS
22 PIPELINE DRUGS
28 RECENT EVENTS AND ANALYST OPINION
28 Mounjaro for Obesity (April 28, 2022)
30 Ozempic for Obesity (June 26, 2021)
33 Tirzepatide for Obesity (June 25, 2021)
37 Ozempic for Obesity (February 10, 2021)
40 KEY UPCOMING EVENTS
41 KEY REGULATORY EVENTS
41 Scotland Okays Funding For Novo Nordisk’s Saxenda
41 Imcivre Needs More Subgroup Analyses Of Clinical Efficacy
41 England Funding Win for Wegovy
42 Novo Nordisk’s Wegovy Gets EU Thumbs Up But Launch Will Wait
42 Wegovy Is Novo Nordisk’s GLP-1 Agonist In A New Guise For Obesity
43 PROBABILITY OF SUCCESS
44 LICENSING AND ASSET ACQUISITION DEALS
44 Novo Nordisk Links Up With EraCal To Develop New Obesity-Related Drug Targets
44 Lilly Teams With Regor On Metabolic Disorders
44 RareStone Licenses Obesity Drug From Rhythm Pharmaceuticals
44 Sciwind Licenses Global Rights To Develop Sanofi’s Long-Lasting GIP Receptor Agonists
45 RNAi Returns To Spotlight As Novo Nordisk Swoops For Dicerna
45 D&D Pharmatech Signs Licensing And Development Agreement For DD01 With Shenzhen Pregene In China
45 CinFina Gets Four Early-Stage Obesity Injectables From Janssen
46 AstraZeneca, Regeneron To Jointly Pursue Novel Metabolic Target
46 NIMIUM Therapeutics And Paraza Pharma Sign Obesity Deal
46 Novo Nordisk To Apply Lumen Technology To Obesity R&D
47 REVENUE OPPORTUNITY
48 CLINICAL TRIAL LANDSCAPE
49 Sponsors by status
50 Sponsors by phase
51 Recent events
54 BIBLIOGRAPHY
55 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in prevalent cases of obesity in adults, 2020–29
16 Figure 2: Trends in prevalent cases of obesity in children and adolescents, 2020–29
22 Figure 3: Overview of pipeline drugs for obesity in the US
22 Figure 4: Pipeline drugs for obesity, by company
23 Figure 5: Pipeline drugs for obesity, by drug type
23 Figure 6: Pipeline drugs for obesity, by classification
30 Figure 7: Mounjaro for Obesity (April 28, 2022): Phase III – SURMOUNT-1
33 Figure 8: Ozempic for Obesity (June 26, 2021): Phase IIIa – STEP 2 (Overweight/obese diabetics)
37 Figure 9: Tirzepatide for Obesity (June 25, 2021): Phase III – SURPASS-2 (vs. Semaglutide)
39 Figure 10: Ozempic for Obesity (February 10, 2021): Phase IIIa – STEP 1 (Weight Loss)
40 Figure 11: Key upcoming events in obesity
43 Figure 12: Probability of success in the obesity pipeline
48 Figure 13: Clinical trials in obesity
48 Figure 14: Top 10 drugs for clinical trials in obesity
49 Figure 15: Top 10 companies for clinical trials in obesity
49 Figure 16: Trial locations in obesity
50 Figure 17: Obesity trials status
51 Figure 18: Obesity trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of obesity in adults, 2020–29
14 Table 2: Prevalent cases of morbid obesity in adults, 2020–29
15 Table 3: Prevalent cases of obesity in children and adolescents, 2020–29
17 Table 4: Prevalence proportions of obesity and morbid obesity, 2020
20 Table 5: Marketed drugs for obesity
24 Table 6: Pipeline drugs for obesity in the US
28 Table 7: Mounjaro for Obesity (April 28, 2022)
31 Table 8: Ozempic for Obesity (June 26, 2021)
33 Table 9: Tirzepatide for Obesity (June 25, 2021)
38 Table 10: Ozempic for Obesity (February 10, 2021)
47 Table 11: Historical global sales, by drug ($m), 2017–21
47 Table 12: Forecasted global sales, by drug ($m), 2022–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
2022 ASCO Weekend Update 
Sign up to the